Header - Therapeutics



Therapeutic Antibodies - An Overview

Monoclonal antibodies have proven to be excellent treatments for a variety of oncology and autoimmune diseases as well as other disease areas.  Currently, over 25% of all drugs in the FDA pipeline are monoclonal antibody (fully human antibodies clearly being the preference) based and this segment of the market has seen compound annual growth at a rate of over 14%.  This market was over $30B USD in 2010 and is expected to be over $60B USD soon.  In short, the need for quality antibody treatments is evident and increasing.  Unfortunately, as the need is increasing, the number of providers that are able to offer this service to clients has decreased.  This is because companies that used to offer these services have been bought by companies that have chosen to keep all development internal, tightening up a very complicated intellectual property landscape.  As a result, there are now very few companies globally that can offer therapeutic antibody development services.

NeoClone has been actively working on developing a proprietary approach for the development of antibodies for therapeutic use. In order to fully capitalize on recent scientific advances, we have begun to offer single-domain antibody services (SdAb).

Single-domain antibodies represent the smallest antibody with proven diagnostic and therapeutic usefulness. In particular, they combine the benefits of conventional antibodies with important features of small molecule drugs. In addition, single-domain antibodies are able to bind to hidden epitopes that are not accessible to whole antibodies due to steric considerations. Also, in comparison with small molecule drugs that target enzyme active sites and receptor clefts, single domain antibodies have the potential of greater affinity and selectivity, thus promising lower side effects and increased efficacy. Furthermore, because of their small size (they are only 1/10th the size of a whole antibody), single domain antibodies can penetrate tissues faster than other antibodies, and even break through the brain´s blood barrier, which turns them into excellent candidates for central nervous system disease therapies. Single domain antibodies have higher stability to changes in temperature and chemical environments, and have the great potential of gastrointestinal stability and oral availability. Also, due to its simple nature of a single-chain peptide, single domain antibodies have exceptional drug format flexibility and allow efficient drug discovery and development.

If you would like to learn more about NeoClone's recent movements into the therapeutic antibody field, please contact Deven at (608)260-8190, or email him at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .